NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2020.1721169
Abstract: Nonalcoholic steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease (NAFLD), is becoming a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC). In fact, NASH has become the leading indication for listing and… read more here.
Keywords: expert opinion; nash nafld; drug; development ... See more keywords